Christopher Waddick
Finanzdirektor/CFO bei CARDIOL THERAPEUTICS INC.
Vermögen: 202 400 $ am 30.04.2024
Aktive Positionen von Christopher Waddick
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CARDIOL THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 19.05.2022 | - |
Finanzdirektor/CFO | 16.08.2018 | - | |
Unternehmenssekretär | 16.08.2018 | - | |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Finanzdirektor/CFO | 01.01.2013 | - |
Präsident | 01.01.2013 | - | |
Nrj Consulting, Inc. | Präsident | 01.11.2009 | - |
Karriereverlauf von Christopher Waddick
Ehemalige bekannte Positionen von Christopher Waddick
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Vorstandsvorsitzender | - | - |
Geschäftsführer | 01.07.2005 | 01.06.2007 | |
Finanzdirektor/CFO | 01.06.2007 | 23.10.2009 |
Ausbildung von Christopher Waddick
York University | Masters Business Admin |
Wilfrid Laurier University | Undergraduate Degree |
Statistik
International
Kanada | 6 |
Vereinigte Staaten | 2 |
Operativ
Director of Finance/CFO | 3 |
President | 2 |
Chief Executive Officer | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Utilities | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CARDIOL THERAPEUTICS INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Utilities |
Nrj Consulting, Inc. |
- Börse
- Insiders
- Christopher Waddick
- Erfahrung